Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease

Ravi Thadhani, Evan Appelbaum, Yuchiao Chang, Yili Pritchett, Ishir Bhan, Rajiv Agarwal, Carmine Zoccali, Christoph Wanner, Donald Lloyd-Jones, Jorge Cannata, Taylor Thompson, Paul Audhya, Dennis Andress, Wuyan Zhang, Jun Ye, David Packham, Bhupinder Singh, Daniel Zehnder, Warren J. Manning, Ajay PachikaScott D. Solomon

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: In chronic kidney disease (CKD), left ventricular hypertrophy (LVH) is prevalent and is associated with increased cardiovascular morbidity and mortality. Vitamin D receptor (VDR) activation attenuates LVH progression in animal models. Methods: PRIMO is a multinational, randomized, double-blinded trial with oral paricalcitol in subjects with stages 3-4 CKD, mild-to-moderate LVH and an LV ejection fraction >50%. The primary endpoint is change in the left ventricular mass index (LVMI) compared with placebo after 48 weeks of treatment. The main secondary endpoints are changes in diastolic function parameters. In this paper, we report baseline characteristics from this study. Results: LVMI was 33.0 ± 7.5 g/m 2.7 for males and 30.8 ± 7.2 g/m 2.7 for females (p = 0.04). LVMI correlated with systolic blood pressure (r = 0.24), urine albumin creatinine ratio (r = 0.39), troponin T (r = 0.29), high-sensitivity C-reactive protein (r = 0.25) and plasma levels of B-type brain natriuretic peptide (r = 0.22); all p < 0.01. In multiple linear regression, each remained independently associated with LVMI. The early diastolic velocity of the lateral mitral annulus (E') was 8.1 ± 2.4 cm/s. E' was inversely correlated with age in univariate (r = -0.14, p = 0.04) and multivariable (p = 0.02) analysis. Conclusion: Among 227 multinational subjects with stages 3-4 CKD, baseline LVMI correlates with baseline blood pressure, urine albumin creatinine ratio and cardiac biomarkers, and baseline diastolic function correlates with age. This research was funded by Abbott Laboratories; ClinicalTrials.gov No. NCT00497146.

Original languageEnglish
Pages (from-to)139-149
Number of pages11
JournalAmerican Journal of Nephrology
Volume33
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Calcitriol Receptors
Kidney Diseases
Left Ventricular Hypertrophy
Chronic Renal Insufficiency
Brain Natriuretic Peptide
Blood Pressure
Albumins
Creatinine
Urine
Troponin T
C-Reactive Protein
Linear Models
Animal Models
Biomarkers
Placebos
Morbidity
Mortality
Research
Therapeutics

Keywords

  • Chronic kidney disease
  • Left ventricular hypertrophy
  • Vitamin D receptor

ASJC Scopus subject areas

  • Nephrology

Cite this

Thadhani, R., Appelbaum, E., Chang, Y., Pritchett, Y., Bhan, I., Agarwal, R., ... Solomon, S. D. (2011). Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. American Journal of Nephrology, 33(2), 139-149. https://doi.org/10.1159/000323551

Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. / Thadhani, Ravi; Appelbaum, Evan; Chang, Yuchiao; Pritchett, Yili; Bhan, Ishir; Agarwal, Rajiv; Zoccali, Carmine; Wanner, Christoph; Lloyd-Jones, Donald; Cannata, Jorge; Thompson, Taylor; Audhya, Paul; Andress, Dennis; Zhang, Wuyan; Ye, Jun; Packham, David; Singh, Bhupinder; Zehnder, Daniel; Manning, Warren J.; Pachika, Ajay; Solomon, Scott D.

In: American Journal of Nephrology, Vol. 33, No. 2, 03.2011, p. 139-149.

Research output: Contribution to journalArticle

Thadhani, R, Appelbaum, E, Chang, Y, Pritchett, Y, Bhan, I, Agarwal, R, Zoccali, C, Wanner, C, Lloyd-Jones, D, Cannata, J, Thompson, T, Audhya, P, Andress, D, Zhang, W, Ye, J, Packham, D, Singh, B, Zehnder, D, Manning, WJ, Pachika, A & Solomon, SD 2011, 'Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease', American Journal of Nephrology, vol. 33, no. 2, pp. 139-149. https://doi.org/10.1159/000323551
Thadhani, Ravi ; Appelbaum, Evan ; Chang, Yuchiao ; Pritchett, Yili ; Bhan, Ishir ; Agarwal, Rajiv ; Zoccali, Carmine ; Wanner, Christoph ; Lloyd-Jones, Donald ; Cannata, Jorge ; Thompson, Taylor ; Audhya, Paul ; Andress, Dennis ; Zhang, Wuyan ; Ye, Jun ; Packham, David ; Singh, Bhupinder ; Zehnder, Daniel ; Manning, Warren J. ; Pachika, Ajay ; Solomon, Scott D. / Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. In: American Journal of Nephrology. 2011 ; Vol. 33, No. 2. pp. 139-149.
@article{126d7027d77344d3b5f5d78bda59def6,
title = "Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease",
abstract = "Background: In chronic kidney disease (CKD), left ventricular hypertrophy (LVH) is prevalent and is associated with increased cardiovascular morbidity and mortality. Vitamin D receptor (VDR) activation attenuates LVH progression in animal models. Methods: PRIMO is a multinational, randomized, double-blinded trial with oral paricalcitol in subjects with stages 3-4 CKD, mild-to-moderate LVH and an LV ejection fraction >50{\%}. The primary endpoint is change in the left ventricular mass index (LVMI) compared with placebo after 48 weeks of treatment. The main secondary endpoints are changes in diastolic function parameters. In this paper, we report baseline characteristics from this study. Results: LVMI was 33.0 ± 7.5 g/m 2.7 for males and 30.8 ± 7.2 g/m 2.7 for females (p = 0.04). LVMI correlated with systolic blood pressure (r = 0.24), urine albumin creatinine ratio (r = 0.39), troponin T (r = 0.29), high-sensitivity C-reactive protein (r = 0.25) and plasma levels of B-type brain natriuretic peptide (r = 0.22); all p < 0.01. In multiple linear regression, each remained independently associated with LVMI. The early diastolic velocity of the lateral mitral annulus (E') was 8.1 ± 2.4 cm/s. E' was inversely correlated with age in univariate (r = -0.14, p = 0.04) and multivariable (p = 0.02) analysis. Conclusion: Among 227 multinational subjects with stages 3-4 CKD, baseline LVMI correlates with baseline blood pressure, urine albumin creatinine ratio and cardiac biomarkers, and baseline diastolic function correlates with age. This research was funded by Abbott Laboratories; ClinicalTrials.gov No. NCT00497146.",
keywords = "Chronic kidney disease, Left ventricular hypertrophy, Vitamin D receptor",
author = "Ravi Thadhani and Evan Appelbaum and Yuchiao Chang and Yili Pritchett and Ishir Bhan and Rajiv Agarwal and Carmine Zoccali and Christoph Wanner and Donald Lloyd-Jones and Jorge Cannata and Taylor Thompson and Paul Audhya and Dennis Andress and Wuyan Zhang and Jun Ye and David Packham and Bhupinder Singh and Daniel Zehnder and Manning, {Warren J.} and Ajay Pachika and Solomon, {Scott D.}",
year = "2011",
month = "3",
doi = "10.1159/000323551",
language = "English",
volume = "33",
pages = "139--149",
journal = "American Journal of Nephrology",
issn = "0250-8095",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease

AU - Thadhani, Ravi

AU - Appelbaum, Evan

AU - Chang, Yuchiao

AU - Pritchett, Yili

AU - Bhan, Ishir

AU - Agarwal, Rajiv

AU - Zoccali, Carmine

AU - Wanner, Christoph

AU - Lloyd-Jones, Donald

AU - Cannata, Jorge

AU - Thompson, Taylor

AU - Audhya, Paul

AU - Andress, Dennis

AU - Zhang, Wuyan

AU - Ye, Jun

AU - Packham, David

AU - Singh, Bhupinder

AU - Zehnder, Daniel

AU - Manning, Warren J.

AU - Pachika, Ajay

AU - Solomon, Scott D.

PY - 2011/3

Y1 - 2011/3

N2 - Background: In chronic kidney disease (CKD), left ventricular hypertrophy (LVH) is prevalent and is associated with increased cardiovascular morbidity and mortality. Vitamin D receptor (VDR) activation attenuates LVH progression in animal models. Methods: PRIMO is a multinational, randomized, double-blinded trial with oral paricalcitol in subjects with stages 3-4 CKD, mild-to-moderate LVH and an LV ejection fraction >50%. The primary endpoint is change in the left ventricular mass index (LVMI) compared with placebo after 48 weeks of treatment. The main secondary endpoints are changes in diastolic function parameters. In this paper, we report baseline characteristics from this study. Results: LVMI was 33.0 ± 7.5 g/m 2.7 for males and 30.8 ± 7.2 g/m 2.7 for females (p = 0.04). LVMI correlated with systolic blood pressure (r = 0.24), urine albumin creatinine ratio (r = 0.39), troponin T (r = 0.29), high-sensitivity C-reactive protein (r = 0.25) and plasma levels of B-type brain natriuretic peptide (r = 0.22); all p < 0.01. In multiple linear regression, each remained independently associated with LVMI. The early diastolic velocity of the lateral mitral annulus (E') was 8.1 ± 2.4 cm/s. E' was inversely correlated with age in univariate (r = -0.14, p = 0.04) and multivariable (p = 0.02) analysis. Conclusion: Among 227 multinational subjects with stages 3-4 CKD, baseline LVMI correlates with baseline blood pressure, urine albumin creatinine ratio and cardiac biomarkers, and baseline diastolic function correlates with age. This research was funded by Abbott Laboratories; ClinicalTrials.gov No. NCT00497146.

AB - Background: In chronic kidney disease (CKD), left ventricular hypertrophy (LVH) is prevalent and is associated with increased cardiovascular morbidity and mortality. Vitamin D receptor (VDR) activation attenuates LVH progression in animal models. Methods: PRIMO is a multinational, randomized, double-blinded trial with oral paricalcitol in subjects with stages 3-4 CKD, mild-to-moderate LVH and an LV ejection fraction >50%. The primary endpoint is change in the left ventricular mass index (LVMI) compared with placebo after 48 weeks of treatment. The main secondary endpoints are changes in diastolic function parameters. In this paper, we report baseline characteristics from this study. Results: LVMI was 33.0 ± 7.5 g/m 2.7 for males and 30.8 ± 7.2 g/m 2.7 for females (p = 0.04). LVMI correlated with systolic blood pressure (r = 0.24), urine albumin creatinine ratio (r = 0.39), troponin T (r = 0.29), high-sensitivity C-reactive protein (r = 0.25) and plasma levels of B-type brain natriuretic peptide (r = 0.22); all p < 0.01. In multiple linear regression, each remained independently associated with LVMI. The early diastolic velocity of the lateral mitral annulus (E') was 8.1 ± 2.4 cm/s. E' was inversely correlated with age in univariate (r = -0.14, p = 0.04) and multivariable (p = 0.02) analysis. Conclusion: Among 227 multinational subjects with stages 3-4 CKD, baseline LVMI correlates with baseline blood pressure, urine albumin creatinine ratio and cardiac biomarkers, and baseline diastolic function correlates with age. This research was funded by Abbott Laboratories; ClinicalTrials.gov No. NCT00497146.

KW - Chronic kidney disease

KW - Left ventricular hypertrophy

KW - Vitamin D receptor

UR - http://www.scopus.com/inward/record.url?scp=78651409106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651409106&partnerID=8YFLogxK

U2 - 10.1159/000323551

DO - 10.1159/000323551

M3 - Article

C2 - 21242674

AN - SCOPUS:78651409106

VL - 33

SP - 139

EP - 149

JO - American Journal of Nephrology

JF - American Journal of Nephrology

SN - 0250-8095

IS - 2

ER -